|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we assessed the influence of another cannabinoid-related gene, mitogen-activated protein kinase 14 (MAPK14), and potential MAPK14-CNR1 gene-gene interactions in conferring brain volume abnormalities among schizophrenia patients with marijuana abuse/dependence.
|
22850347 |
2013 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cannabinoid receptor 1 (CNR1) gene polymorphisms have been associated with central and peripheral effects of cannabis and schizophrenia pathophysiology.
|
26071625 |
2015 |
|
Marijuana Abuse
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because the psychotropic effects and abuse liability of cannabis prevent its therapeutic application in depression and anxiety states, we decided to investigate the effects of the combination of ineffective doses of cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) and β-carbolines on anxiety- and depression-related behaviors in male NMRI mice.
|
30797851 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant.
|
30077950 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, it is unclear which constituent in cannabis is responsible for these effects, or whether these are cannabinoid receptor 1 (CB1R) mediated.
|
29604295 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
The cannabinoid receptor 1 (CB<sub>1</sub>) is the principal target of the psychoactive constituent of marijuana, the partial agonist Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC).
|
28678776 |
2017 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consumption of cannabinoid receptor-1 (CB-1) agonist such as cannabis is widely taken in 3,4- methylenedioxymethamphetamine (MDMA) or ecstasy users; it has been hypothesized that co-consumption of CB-1 agonist might protect neurons against MDMA toxicity.
|
28167133 |
2017 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synthetic cannabinoids are, typically, full agonists at the cannabinoid CB1 receptor, and therefore considerably more potent than natural cannabis and may have correspondingly more serious psychological effects.
|
30789300 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Yet, very few studies have been designed to directly assess the role of CB1 receptors in mediating the effects of cannabis on human brain function.
|
28414051 |
2017 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vitro studies suggest that synthetic cannabinoids in these preparations are potent agonists at central cannabinoid CB1 receptors (CB1Rs), but few investigations have delineated their cellular effects, particularly in comparison with the psychoactive component of marijuana, Δ<sup>9</sup> -tetrahydrocannabinol (Δ<sup>9</sup> -THC).
|
26732435 |
2017 |
|
Marijuana Abuse
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These studies demonstrate that pathological and behavioral phenotypes associated with FASD are induced by exposure to CB1R agonists and suggest that combined exposure to lower levels of alcohol and marijuana may be capable of inducing FASD-like morphological and behavioral impairments.
|
30648819 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CB1/Cnr1 receptor is the major brain site at which cannabinoid marijuana constituents are psychoactive as well as the principal brain receptor for endogenous anandamide ligands.
|
15289816 |
2004 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cannabinoids are the active ingredients of marijuana, which interact with cannabinoid receptors such as CNR1 and CNR2 to activate cellular signaling pathways.
|
29884300 |
2018 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CNR1 haplotypes were formed from four CNR1 SNPs (rs806368, rs1049353, rs2023239, and rs6454674) and tested with level of cannabis exposure to assess their interactive effects on the lingual gyrus, cingulum (right and left) and rolandic operculum, regions showing cannabis exposure effects in the SPM8 analyses.
|
27500453 |
2016 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
The central cannabinoid receptor (CB1) mediates the pharmacological activities of cannabis, the endogenous agonist anandamide and several synthetic agonists.
|
10441206 |
1999 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of CNR1 tSNPs and marijuana abuse/dependence on brain volumes and neurocognition were assessed using ANCOVA, including co-morbid alcohol/non-marijuana illicit drug misuse as covariates.
|
21420833 |
2011 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A single nucleotide polymorphism in the cannabis receptor-1 gene (CNR1), rs2023239, has been associated with CD diagnosis and intermediate phenotypes, including abstinence-induced withdrawal, cue-elicited craving, and parahippocampal activation to cannabis cues.
|
22669173 |
2012 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Since marijuana intoxication has a potent blocking effect on short-term memory we examined the association between the CNR1 alleles and the P300 wave amplitude at three electrodes in 35 alcohol and drug addicts, by MANOVA.
|
9106243 |
1997 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CNR1 variation emerged as a moderator of the relationship between trait impulsivity and marijuana problems, thus suggesting that marijuana users with CNR1 risk variants and a higher trait impulsivity are at greater risk for developing marijuana-related problems and supporting a role for CNR1 in a broader impulsivity phenotype.
|
24172113 |
2013 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken collectively, the atypical pharmacodynamic properties of AB-PINACA at CB1Rs relative to Δ<sup>9</sup>-THC (e.g., higher potency/efficacy and greater production of desensitization), coupled with an unusual metabolic profile (e.g., production of metabolically stable active phase I metabolites) may contribute to the pronounced adverse effects observed with abuse of this SCB compared to marijuana.
|
30319418 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, DLPFC activity in the cluster associated with the CNR1 by PTGS2 interaction was negatively correlated with behavioral efficiency and positively correlated with frequency of cannabis use in cannabis users.
|
27261878 |
2016 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
To examine whether variants within the cannabinoid receptor (CNR1) and alpha(7) nicotinic receptor (CHRNA7) genes are associated with schizophrenia, and whether these effects vary according to cannabis or tobacco use.
|
17978319 |
2007 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
The cannabinoid-1 receptor (CB1R) agonist Δ9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, adversely effects working memory performance in humans.
|
28641496 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the acute effects of cannabis on anxiety in males are mediated by the modulation of amygdalar function by delta-9-THC and the extent of these effects are related to local availability of CB1 receptors.
|
29101333 |
2017 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using Chinese hamster ovary cells stably transfected with the CB(1) receptor cDNA we show here that Delta(9)-tetrahydrocannabinol (THC), the major active component of marijuana, induces the activation of protein kinase B/Akt (PKB).
|
10749665 |
2000 |